BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251106T130000
DTEND;TZID=America/New_York:20251106T140000
DTSTAMP:20260423T032736
CREATED:20251027T141549Z
LAST-MODIFIED:20251030T171821Z
UID:71702-1762434000-1762437600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Bayer - Jivi - With Them as They Grow™ Clinical Study Data for Children 7 to 11 Yrs
DESCRIPTION:Date: Thursday\, November 6th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n  \n \nWEBINAR TOPIC: \nJivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years. \nOBJECTIVE: \nThis session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data from these studies have been combined\, as each included participants aged 7 to less than 12 years. The studies were conducted to evaluate the safety and clinical effectiveness of Jivi in previously treated individuals within this age group who have severe hemophilia A. Get the latest data and learn how Jivi may fit the needs of your patients starting at age 7. \nIndications: JIVI ® is a recombinant DNA-derived\, Factor VIII concentrate indicated for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for: \n\nOn-demand treatment and control of bleeding episodes.\nPerioperative management of bleeding.\nRoutine prophylaxis to reduce the frequency of bleeding episodes.\n\n  \nLimitations of use JIVI is not indicated for use in: \n\nChildren less than 7 years of age due to a greater risk for hypersensitivity reactions and/or loss of efficacy.\nPreviously untreated patients (PUPs).\nTreatment of von Willebrand disease.\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nDr. Akshat Jain MD\, MPH \nDirector of Sickle Cell Center of Excellence; Faculty Clinical Medicine and Pediatrics; Hematology Oncology and Cell Therapy; Loma Linda University School of Medicine
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bayer-jivi-with-them-as-they-growclinical-study-data-for-children-7-to-11-yrs/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T130000
DTEND;TZID=America/New_York:20251112T140000
DTSTAMP:20260423T032736
CREATED:20251029T145821Z
LAST-MODIFIED:20251029T150136Z
UID:71751-1762952400-1762956000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - VONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients
DESCRIPTION:Date: Wednesday\, November 12th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nVONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients. \nOBJECTIVE: \n\nUnderstand the underlying mechanism of VWD and the role of VWF.\nReview unmet needs in the treatment of VWD.\nIdentify the unique characteristics of VONVENDI as the first and only recombinant treatment for patients with VWD.\nReview hypothetical patient cases and clinical data for on-demand\, prophylactic\, and surgical control of bleeds with VONVENDI.\n\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nDr. Jonathan Roberts \nDr. Roberts graduated from the Southern Illinois School of Medicine in 2008 and completed his internship and residency in Pediatrics at the University of Illinois College of Medicine at Peoria at OSF HealthCare Children’s Hospital of Illinois in 2011. After finishing his residency\, Dr. Roberts completed fellowship in Pediatric Hematology/Oncology/Blood & Marrow Transplantation at the Medical College of Wisconsin/Children’s Hospital of Wisconsin in 2014 and worked as a post-doctoral fellow under Dr. Robert Montgomery and Dr. Joan Cox Gill at the Blood Center of Wisconsin Blood Research Institute. In addition to being the Associate Medical Director/Associate Research Director of BCDI\, Dr. Roberts is also an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria\, IL. \nDr. Roberts’ research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia\, VWD\, and other rare bleeding and classical hematologic disorders. He has received numerous young investigator research awards\, has over 100 peer-reviewed research publications and abstracts including lead/senior author publications in Blood\, the Journal of Thrombosis and Haemostasis\, and the New England Journal of Medicine; and has had grant funding from the National Bleeding Disorders Foundation\, World Federation of Hemophilia and National Institutes of Health among others. \nDr. Roberts has a personal passion for the bleeding disorders community as he is also an individual with severe hemophilia A. \nDisclosures: \nNovo Nordisk\, Octapharma\, Sanofi\, Takeda\, Genentech\, Pfizer\, F. Hoffmann-La Roche AG
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-vonvendi-von-willebrand-factor-recombinant-now-approved-for-adults-and-pediatric-patients/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251113T130000
DTEND;TZID=America/New_York:20251113T140000
DTSTAMP:20260423T032736
CREATED:20251027T142835Z
LAST-MODIFIED:20251027T142835Z
UID:71706-1763038800-1763042400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - The HEMGENIX Toolkit
DESCRIPTION:Date: Thursday\, November 13th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nWEBINAR TOPIC: \nThe HEMGENIX Toolkit \nOBJECTIVE: \nOverview of the tools and resources available to treatment centers to help support patients eligible and interested in HEMGENIX \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nBonnie Ben-Shmuel \nBonnie Ben-Shmuel is a seasoned biopharmaceutical marketing leader with over a decade of experience driving commercial strategy\, cross-functional execution\, and transformational growth across gene therapy\, rare disease\, immunology\, and oncology. As Director of U.S. Marketing for HEMGENIX\, she has led initiatives that expanded treatment center readiness\, streamlined patient access\, and accelerated gene therapy adoption.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-csl-behring-the-hemgenix-toolkit/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR